Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Update on SAR Studies Toward New COX-1 Selective Inhibitors

Author(s): Paola Vitale, Antonio Scilimati and Maria Grazia Perrone

Volume 22, Issue 37, 2015

Page: [4271 - 4292] Pages: 22

DOI: 10.2174/0929867322666151029104717

Price: $65

Abstract

Few selective cyclooxygenase-1 (COX-1) inhibitors have been described up to now, although recent studies underlined the involvement of COX-1 in the carcinogenesis, pathogenesis of neuroinflammation, cardiovascular diseases and pain. Among the known COX-1 inhibitors none proved to be a good drug candidate, with the exception of mofezolac, that is clinically used as an analgesic drug. New selective inhibitors were very often discovered as a minor achievement during SAR investigations to discover selective COX-2 inhibitors (COXIBs). After a recognition of the new COX-1 inhibitors synthesized in the last five years, it was attempted to draw, for each chemical class, a structure which might highlight the determinant molecular features able to switch the selectivity towards the COX-1 isoform. Overall, this review could constitute a tool to a better design of novel selective COX-1 inhibitors, to be used in a disease theranostic approach targeting COX-1.

Keywords: Cyclooxygenase (COX)-1, COX-2, structure-activity relationship(SAR), diarylheterocycles, benzanilides, arylpropanoic acids, stilbenes, NSAIDs.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy